PAX8 expression reliably distinguishes pancreatic well-differentiated neuroendocrine tumors from Heal and pulmonary well-differentiated neuroendocrine tumors and pancreatic acinar cell carcinoma

被引:86
作者
Sangoi, Ankur R. [1 ,2 ]
Ohgami, Robert S. [2 ]
Pai, Rish K. [3 ]
Beck, Andrew H. [2 ]
McKenney, Jesse K. [2 ]
Pai, Reetesh K. [2 ]
机构
[1] El Camino Hosp, Dept Pathol, Mountain View, CA 94040 USA
[2] Stanford Univ, Dept Pathol, 300 Pasteur Dr,Room H-2110, Stanford, CA 94305 USA
[3] Washington Univ, Dept Pathol, St Louis, MO 63130 USA
关键词
carcinoid; endocrine tumor; immunohistochemistry; neuroendocrine tumor; pancreas; pancreatic; PAX8; TRANSCRIPTION FACTOR-I; SOLID-PSEUDOPAPILLARY TUMORS; ENDOCRINE TUMORS; PROGNOSTIC-FACTORS; BETA-CATENIN; MARKER; CDX2; TTF-1; TEMOZOLOMIDE; NEOPLASMS;
D O I
10.1038/modpathol.2010.176
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
PAX (paired box) genes encode a family of transcription factors that regulate organogenesis in a variety of organs. Very little is known about the role of PAX8 in endocrine cell development and the expression of PAX8 in neuroendocrine tumors. The purpose of this study was to analyze PAX8 immunohistochemical expression in gastroenteropancreatic and pulmonary well-differentiated neuroendocrine tumors to determine whether PAX8 can reliably distinguish pancreatic neuroendocrine tumors from neuroendocrine tumors of other anatomic sites and other pancreatic non-ductal neoplasms. In total, 221 well-differentiated neuroendocrine tumors were evaluated: 174 primary neuroendocrine tumors (66 pancreatic, 31 Heal, 21 pulmonary, 20 gastric, 17 rectal, 11 appendiceal, and 8 duodenal) and 47 neuroendocrine tumors metastatic to the liver (31 pancreatic, 11 Heal, 2 pulmonary, 2 duodenal, and 1 rectal). Fifteen solid-pseudopapillary neoplasms and six acinar cell carcinomas of the pancreas were also evaluated. PAX8 was positive in 49/66 (74%) primary pancreatic neuroendocrine tumors. PAX8 expression did not correlate with World Health Organization categorization, grade, size, functional status, or the presence of liver or lymph node metastasis. PAX8 expression was identified in 0/31 (0%) ileal, 0/21 (0%) pulmonary, 2/20 (10%) gastric, 5/17 (29%) rectal, 1/11 (9%) appendiceal, and 6/8 (75%) duodenal neuroendocrine tumors. PAX8 was positive in 4/15 (27%) solid-pseudopapillary neoplasms of the pancreas, whereas all acinar cell carcinomas (0/6) lacked immunoreactivity. Among liver metastases, only pancreatic neuroendocrine tumors (20/31, 65%) were PAX8 positive, whereas no cases of Heal (0/11), pulmonary (0/2), duodenal (0/2), and rectal (0/1) neuroendocrine tumor metastases were PAX8 positive. PAX8 is expressed in primary and metastatic pancreatic well-differentiated neuroendocrine tumors, and its expression can reliably distinguish pancreatic from Heal and pulmonary well-differentiated neuroendocrine tumors. Duodenal neuroendocrine tumors and a subset of rectal, gastric, and appendiceal neuroendocrine tumors may also express PAX8. PAX8 expression can distinguish pancreatic neuroendocrine tumors from acinar cell carcinomas, but its utility in distinguishing neuroendocrine tumors from solid-pseudopapillary neoplasms is limited. Modern Pathology (2011) 24, 412-424; doi:10.1038/modpathol.2010.176; published online 1 October 2010
引用
收藏
页码:412 / 424
页数:13
相关论文
共 46 条
[1]   Solid-pseudopapillary tumors of the pancreas are genetically distinct from pancreatic ductal adenocarcinomas and almost always harbor β-catenin mutations [J].
Abraham, SC ;
Klimstra, DS ;
Wilentz, RE ;
Yeo, CJ ;
Conlon, K ;
Brennan, M ;
Cameron, JL ;
Wu, TT ;
Hruban, RH .
AMERICAN JOURNAL OF PATHOLOGY, 2002, 160 (04) :1361-1369
[2]   Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumors [J].
Agoff, SN ;
Lamps, LW ;
Philip, AT ;
Amin, MB ;
Schmidt, RA ;
True, LD ;
Folpe, AL .
MODERN PATHOLOGY, 2000, 13 (03) :238-242
[3]   CDX-2 homeobox gene product expression in neuroendocrine tumors - Its role as a marker of intestinal neuroendocrine tumors [J].
Barbareschi, M ;
Roldo, C ;
Zamboni, G ;
Capelli, P ;
Cavazza, A ;
Macri, E ;
Cangi, MG ;
Chilosi, M ;
Doglioni, C .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2004, 28 (09) :1169-1176
[4]  
BEASLEY MB, 2004, CARCINOID TUMOR
[5]   Cytokeratin 7 and 20 and thyroid transcription factor 1 can help distinguish pulmonary from gastrointestinal carcinoid and pancreatic endocrine tumors [J].
Cai, YC ;
Banner, B ;
Glickman, J ;
Odze, RD .
HUMAN PATHOLOGY, 2001, 32 (10) :1087-1093
[6]   Cdx2 as a marker for neuroendocrine tumors of unknown primary sites [J].
Erickson, LA ;
Papouchado, B ;
Dimashkieh, H ;
Zhang, SY ;
Nakamura, N ;
Lloyd, RV .
ENDOCRINE PATHOLOGY, 2004, 15 (03) :247-252
[7]  
Folpe AL, 1999, MODERN PATHOL, V12, P5
[8]   Neuroendocrine tumors of the diffuse neuroendocrine system [J].
Gustafsson, Bjorn I. ;
Kidd, Mark ;
Modlin, Irvin M. .
CURRENT OPINION IN ONCOLOGY, 2008, 20 (01) :1-12
[9]  
Hemminki K, 2001, CANCER, V92, P2204, DOI 10.1002/1097-0142(20011015)92:8<2204::AID-CNCR1564>3.0.CO
[10]  
2-R